司美格鲁肽治疗合并肥胖的心血管疾病研究进展  

Research progress of semaglutide in the treatment of cardiovascular diseases complicated with obesity

作　　者：马庆 贾建旗 何倩[1] MA Qing;JIA Jianqi;HE Qian(Department of Outpatient,the 989th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China,Luoyang 471003,Henan Province,China)

机构地区：[1]中国人民解放军第九八九医院派驻门诊部,河南洛阳471003

出　　处：《世界临床药物》2024年第10期1099-1103,共5页World Clinical Drug

摘　　要：司美格鲁肽(semaglutide)于2024年3月8日获美国食品药品监督管理局批准用于超重或肥胖(obesity)的成年人群心血管疾病、心脏病及脑卒中(cerebral apoplexy)等的预防。司美格鲁肽可改善肥胖患者的血糖和传统心血管中等风险因子水平,并减少可能导致动脉粥样硬化(atheroscherosis)和心肌功能障碍的异位脂肪组织,改善与肥胖相关的全身性促炎及促血栓形成环境。现拟从多途径、多层次阐述司美格鲁肽治疗合并肥胖的心血管疾病作用机制、临床研究及安全性,为临床用药提供一定参考。Semaglutide was approved by the U.S.Food and Drug Administration on March 8,2024 for the prevention of cardiovascular disease,heart disease,and cerebral apoplexy in adults who are overweight or obese.Semaglutide improves blood glucose and traditional cardiovascular moderate risk factor levels in obese patients,reduces ectopic adipose tissue that can lead to atherosclerosis and myocardial dysfunction,and improves the systemic pro-inflammatory and pro thrombotic environment associated with obesity.This article intended to elaborate the mechanism of action,clinical research and safety of semaglutide in the treatment of cardiovascular diseases complicated with obesity from multiple ways and levels,so as to provide certain reference for clinical use.

关 键 词：司美格鲁肽 肥胖 心血管疾病 

分 类 号：R977[医药卫生—药品] R587.1[医药卫生—药学] R587.1